FDA Approves First Gene - Based Test to Detect the Spread of Breast Cancer into Lymph Nodes
News Jul 17, 2007
Veridex, LLC , a Johnson & Johnson company, has announced US Food and Drug Administration (FDA) approval of the first intra-operative and gene-based test to detect the spread of breast cancer into the lymph nodes.
The GeneSearch™ Breast Lymph Node (BLN) Assay can detect the spread of cancer into the lymph nodes more accurately than existing rapid methodologies and, as a result, has the potential to reduce the need for stressful and costly second surgeries for breast cancer patients.
“Given that more than 40,000 women in the U.S. die from breast cancer annually, the demand for better medical care is extraordinarily high,” said Pat Whitworth, M.D., director of the Nashville Breast Center and a principal investigator in the GeneSearch™ BLN clinical trials.
“With this new molecular pathology test, we have an opportunity to improve the standard of care for women with this disease. Patients and physicians now can have a higher degree of confidence in their lymph node test results and, as a result, make more informed decisions about their treatment.”
The GeneSearch™ BLN Assay is the first in vitro diagnostic test approved in the United States for the detection of metastases greater than 0.2 mm in sentinel lymph node tissue removed from breast cancer patients.
According to Company, in clinical trials with more than 300 patients in the U.S. that compared performance of GeneSearch™ with commonly performed intra-operative test procedures, GeneSearch™ correctly identified 95.6 percent of patients who had metastases in their lymph nodes. This high accuracy in finding metastases was statistically superior to the most commonly performed intra-operative test procedure.
The new, gene-based technology of the GeneSearch™ test allows for the analysis of 50 percent of the sentinel node, versus five percent of tissue typically examined under a microscope for evidence of cancer cells. Test results from GeneSearch™ can be produced in 35 to 40 minutes during the initial surgical procedure versus two to three days with tissue pathology.
“Too often, women who have had breast cancer surgery are forced to return for a second operation to remove lymph nodes,” said Peter Blumencranz, M.D., medical director, Breast Health Services, Morton Plant Mease Healthcare in Clearwater, Florida. “The GeneSearch™ BLN test has the potential to change that by more accurately guiding decisions during surgery, in real-time, thereby reducing the risks, stress, emotional trauma and costs of second surgeries.”
“There is a need for a more accurate test to detect metastasized breast cancer in a woman’s lymphatic tissue – and that’s where the GeneSearch™ BLN Assay comes in,” said Ken Berlin, general manager, Veridex. “We now have the opportunity to detect some metastases that could be missed by other tests. The end result is better patient management and better patient standard of care.”
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE
Mouse Model Demonstrates Potential of New Autism DrugNews
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, largely corrected electrical, behavioral and brain abnormalities in the mice.READ MORE